Clear Search

Showing 2 results for “Spinar J”.

Obesity and Effects of Dapagliflozin on Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 trial

Eur Heart J 2022;43:2958-67 doi.org/10.1093/eurheartj/ehab530

In the DECLARE-TIMI 58 trial, patients with type 2 diabetes and higher body weight were more likely to have hospitalisation for heart failure (HHF) and atrial fibrillation or flutter (AF/AFL).

Read more…

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

N Engl J Med 2020;383:1413–24 DOI 10.1056/NEJMoa2022190

Empagliflozin demonstrated a reduction in CV death, HF hospitalisation, rate of eGFR decline and risk of serious renal outcomes in patients with chronic HF and reduced ejection fraction in the EMPEROR-reduced study.

Read more…